Article 1 Licensing
Section 1 (245A.1915) requires all programs licensed by the commissioner to provide educational information concerning treatment options for opioid addiction to clients identified as having or seeking treatment of opioid addiction. The commissioner shall develop the educational materials.
Section 2 (245A.192, subd. 1) specifies that this section of law applies to services licensed to provide treatment for opioid addiction.
Subdivision 2 defines the following terms:
-
"Diversion"
-
"Guest dose or dosing"
-
"Medical director"
-
"Medication used for the treatment of opioid addiction"
-
"Minnesota health care programs"
-
"Opioid treatment program"
-
"Placing authority"
-
"Program"
-
"Unsupervised use"
Subdivision 3 provides the requirements prior to administering or dispensing a medication used for the treatment of opioid addiction.
Subdivision 4 requires a minimum of eight random drug tests over a 12-month period for clients in the program. A license holder may elect to conduct more drug tests.
Subdivision 5 specifies the criteria that must be met before a client may be dispensed medication for unsupervised or take-home use outside of the program.
Subdivision 6 imposes restrictions and timelines for clients who meet the criteria under subdivision 5 for unsupervised or take-home use.
Subdivision 7 requires a provider to meets certain requirements in order to accelerate the number of unsupervised or take-home doses. The commissioner is given authority to monitor for compliance and may issue licensing actions for noncompliance.
Subdivision 8 allows individuals to receive treatment at a different clinic, which is “guest dosing,” under certain circumstances.
Subdivision 9 requires the license holder to submit data regarding medication used for treatment to a central registry, effective upon implementation of the federal system or the development of another electronic system.
Subdivision 10, paragraph (a) modifies the nonmedication treatment services that a program must offer and paragraph (b) clarifies contents of the treatment plan and progress notes in the client’s file.
Subdivision 11 provides that, upon admission, the client will be notified that the medical director will be monitoring the prescription monitoring program to review prescribed controlled drug use. Subsequent reviews will occur quarterly, unless there is recent history of multiple prescribers, then the reviews will occur monthly.
Paragraph (b) requires the commissioner to collaborate with the Minnesota Board of Pharmacy to develop and implement an electronic system through which the commissioner shall routinely access the data from the prescription monitoring program to determine if a client has been prescribed controlled substances in addition to the prescriptions by the opioid treatment program. Sets forth requirements when the commissioner determines there are multiple prescribers or prescriptions.
Subdivision 12 requires license holders to develop and maintain the policies and procedures in this subdivision, which include policies to provide medication when the program is closed, to reduce the possibility of the medication being used for an unintended purpose, to ensure state and federal laws are followed when ordering, administering, and dispensing medications.
Subdivision 13 requires the license holder to develop and maintain a quality improvement process and plan, as specified in this subdivision.
Subdivision 14 requires programs to provide notification and client-specific updates to placing agencies for clients who are enrolled in Minnesota health care programs. At the request of the placing agency, the program must provide client-specific updates, including positive drug screenings and changes in medications.
Article 2 Chemical and Mental Health
Section 1 (254B.04) adds new paragraph (b) requiring the assessor to provide information, prior to placement, concerning treatment options for opioid addiction.
Article 3 Controlled Substances Prescription Monitoring Program
Section 1 (152.01, subd. 5a) changes a cross-reference to section 2.
Section 2 (152.126, subd. 2) modifies the list of Schedule I controlled substances, by adding to the list of hallucinogens and marijuana.
Section 2 (152.126, subd. 6) allows the commissioner, within available appropriations, to access data to determine multiple prescriptions or prescribers, and requires the commissioner to seek a waiver to allow access to the data, if necessary.
|